4.6 Article

Maternal 17q21 genotype influences prenatal vitamin D effects on offspring asthma/recurrent wheeze

Journal

EUROPEAN RESPIRATORY JOURNAL
Volume 58, Issue 3, Pages -

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/13993003.02012-2020

Keywords

-

Funding

  1. National Heart, Lung, and Blood Institute [R01HL091528, UH3OD023268, R01HL141826, K01HL146980]
  2. Jane and Aatos Erkko Foundation
  3. Paulo Foundation
  4. Pediatric Research Foundation
  5. National Institutes of Health [P01HL132825]
  6. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [946228]

Ask authors/readers for more resources

Prenatal vitamin D-3 supplementation has a protective effect against offspring asthma/recurring wheeze, which is influenced by maternal 17q21 genotype variation. Offspring of mothers with low-risk genotype show significant reduction in risk with high-dose vitamin D-3 supplementation, while no difference was observed in offspring of mothers with high-risk genotype.
Background Prenatal vitamin D-3 supplementation has been linked to reduced risk of early-life asthma/recurrent wheeze. This protective effect appears to be influenced by variations in the 17q21 functional single nucleotide polymorphism rs12936231 of the child, which regulates the expression of ORMDL3 (ORM1-like 3) and for which the high-risk CC genotype is associated with early-onset asthma. However, this does not fully explain the differential effects of supplementation. We investigated the influence of maternal rs12936231 genotype variation on the protective effect of prenatal vitamin D-3 supplementation against offspring asthma/recurrent wheeze. Methods We determined the rs12936231 genotype of mother-child pairs from two randomised controlled trials: the Vitamin D Antenatal Asthma Reduction Trial (VDAART, n=613) and the Copenhagen Prospective Studies on Asthma in Childhood 2010 (COPSAC(2010), n=563), to examine the effect of maternal genotype variation on offspring asthma/recurrent wheeze at age 0-3 years between groups who received high-dose prenatal vitamin D-3 supplementation versus placebo. Results Offspring of mothers with the low-risk GG or GC genotype who received high-dose vitamin D-3 supplementation had a significantly reduced risk of asthma/recurrent wheeze when compared with the placebo group (hazard ratio (HR) 0.54, 95% CI 0.37-0.77; p<0.001 for VDAART and HR 0.56, 95% CI 0.35-0.92; p=0.021 for COPSAC(2010)), whereas no difference was observed among the offspring of mothers with the high-risk CC genotype (HR 1.05, 95% CI 0.61-1.84; p=0.853 for VDAART and HR 1.11, 95% CI 0.54-2.28; p=0.785 for COPSAC(2010)). Conclusion Maternal 17q21 genotype has an important influence on the protective effects of prenatal vitamin D-3 supplementation against offspring asthma/recurrent wheeze.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available